INTERLEUKIN-17 IS A NEW TARGET FOR ANTI-CYTOKINE THERAPY OF IMMUNE INFLAMMATORY RHEUMATIC DISEASES
https://doi.org/10.14412/1995-4484-2013-1547
Abstract
As of now, there have been notable advances in treating immune inflammatory rheumatic diseases, which are associated with the interpretation of basic pathogenetic mechanisms of their development. The most well studied therapeutic targets are tumor necrosis factor-α, interleukin (IL)-6 and IL-1; inhibition of these cytokines with genetically engineered biological agents is not always clinically effective and rarely gives rise to remission. The new promising treatment of rheumatoid arthritis (RA) and other inflammatory arthritides is linked to the inhibition of IL-17A, a proinflammatory cytokine, involved in the development of inflammation and in the destruction of bone tissue. The paper summarizes new evidence for the prospects of using anti-interleukin-17 monoclonal antibodies to treat RA.
About the Authors
Evgeny Lvovich Nasonov
V.A. Nasonova Research Institute of Rheumatology, Russian Academy of Medical
Sciences, Moscow
Russian Federation
Russian Federation
L N Denisov
V.A. Nasonova Research Institute of Rheumatology, Russian Academy of Medical
Sciences, Moscow
Russian Federation
Russian Federation
M L Stanislav
V.A. Nasonova Research Institute of Rheumatology, Russian Academy of Medical
Sciences, Moscow
Russian Federation
Russian Federation
References
1. <div><p>Насонов ЕЛ. Современные направления иммунологических исследований при хронических воспалительных и аутоиммунных заболеваниях человека. Терапевтический архив. 2001;(8):43–6. [Nasonov EL. Sovremennye napravleniya immunologicheskikh issledovaniy pri khronicheskikh vospalitel'nykh i autoimmunnykh zabolevaniyakh cheloveka. Terapevticheskiy arkhiv. 2001;(8):43–6.]</p><p>Насонов ЕЛ. Перспективы лечения ревматических заболеваний в начале 21 века. Терапевтический Архив. 2011;(5):5–9. [Nasonov EL. Perspektivy lecheniya revmaticheskikh zabolevaniy v nachale 21 veka. Terapevticheskiy Arkhiv. 2011;(5):5–9.]</p><p>Генно-инженерные биологические биологические препараты в лечении ревматоидного артрита. Под редакцией Насонова ЕЛ. Москва: ИМА-ПРЕСС; 2013. С. 549. [Genno-inzhenernye biologicheskie biologicheskie preparaty v lechenii revmatoidnogo artrita. Nasonov EL, editor. Moscow: IMA-PRESS; 2013. P. 549.]</p><p>Pope J, Combe B. Unmet needs in the treatment of rheumatoid arthritis. J Rheumatol Autoimmue Dis. 2013;3:65–78. DOI: http://dx.doi.org/10.4236%2Fojra.2013.32011.</p><p>Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol. 1989;7:145–73. DOI: http://dx.doi.org/10.1146%2Fannurev.iy.07.040189.001045.</p><p>Zhu S, Qian Y. IL-17/IL-17 receptor system in autoimmune disease: mechanisms and therapeutic potential. Clin Sci. 2012;122(11):487–511. DOI: http://dx.doi.org/10.1042%2FCS20110496.</p><p>Onishi RM, Gaffen SL. Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease. Immunology. 2010;129(3):311–21. DOI: http://dx.doi.org/10.1111%2Fj.1365-2567.2009.03240.x.</p><p>Miossec P. IL-17 and Th17 cells in human inflammatory diseases. Microbes Infect. 2009;11(5):625–30. DOI: http://dx.doi.org/10.1016%2Fj.micinf.2009.04.003.</p><p>Qu N, Xu M, Mizoguchi I et al. Oivotal roles of T-helper 17-telated cytokines, IL-17, IL-22, and IL-23, in inflammatory diseases. Clin Devel Immunol. 2013; ID 968549l.</p><p>Martin DA, Towne JE, Kricorian G et al. The emerging role of IL-17 in the pathogeneasis of psoriasis: preclinical and clinical findings. J Invest Dermatol. 2013;133(1):17–26. DOI: http://dx.doi.org/10.1038%2Fjid.2012.194.</p><p>Qian Y, Kang Z, Liu C, Li X. IL-17 signaling in host defense and inflammatory diseases. Cell Mol Immunol. 2010;7(5):328–33. http://dx.doi.org/10.1038%2Fcmi.2010.27.</p><p>Gaffen SL. Structure and signalling in the IL-17 receptor family. Nat Rev Immunol. 2009;9(8):556–67. DOI: http://dx.doi.org/10.1038%2Fnri2586</p><p>Kimura A, Kishimoto T. IL 6: regulator of Treg/Th17 balance. Eur J Immunol. 2010;40(7):1830–5. DOI: http://dx.doi.org/10.1002%2Feji.201040391.</p><p>Kellner H. Targeting interleukin-17 in patients with active rheumatoid arthritis: rationale and clinical potential. Ther Adv Musculoskeletal Dis. 2013;5(3):141–52. DOI: http://dx.doi.org/10.1177%2F1759720X13485328.</p><p>Gaffen S. Role of IL-17 in the pathogenesis of rheumatoid arthritis. Curr Rheumatol Rep. 2009;11:365–70.</p><p>Sarkar S, Cooney LA, Fox DA. The role of T helper type 17 cells in inflammatory arthritis. Clin Exp Immunol. 2009;159(3):225–37. DOI: http://dx.doi.org/10.1111%2Fj.1365-2249.2009.04016.x.</p><p>Yamada H. Current perspectives on the role of IL-17 in autoimmune disease. J Inflam Res. 2010;3:33–44. DOI: http://dx.doi.org/10.2147%2FJIR.S6375</p><p>Lubbers E. Th17 cytokines and arthritis. Semin Immunopatjol. 2010;04 Feb.</p><p>Nakae S, Nambu A, Sudo K, Iwakura Y. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol. 2003;171(11):6173–7.</p><p>Plater-Zyberk C, Joosten L, Helsen M et al. Combined blockade of granulocyte-macrophage colony stimulating factor and interleukin 17 pathways potently suppresses chronic destructive arthritis in a tumour necrosis factor α-independent mouse model. Ann Rheum Dis. 2009;68:721–8.</p><p>Lubberts E, Koenders M, Oppers-Walgreen B et al. Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum. 2004;50(2):650–9. DOI: http://dx.doi.org/10.1002%2Fart.20001.</p><p>Bush K, Farmer K, Walker J, Kirkham B. Reduction of joint inflammation and bone erosion in rat adjuvant arthritis by treatment with interleukin-17 receptor IgG1 Fc fusion protein. Arthritis Rheum. 2002;46(3):802–5. DOI: http://dx.doi.org/10.1002%2Fart.10173.</p><p>Chao C, Chen S, Adamopoulos I et al. Anti-IL-17A therapy protects against bone erosion in experimental models of rheumatoid arthritis. Autoimmunity. 2011;44(3):243–52. http://dx.doi.org/10.3109%2F08916934.2010.517815.</p><p>Koenders M, Lubberts E, Oppers-Walgreen B et al. Blocking of interleukin-17 during reactivation of experimental arthritis prevents joint inflammation and bone erosion by decreasing RANKL and interleukin-1. Am J Pathol. 2005;167(1):141–9. DOI: http://dx.doi.org/10.1016%2FS0002-9440%2810%2962961-6.</p><p>Ishiguro A, Akiyama T, Adachi H et al. Therapeutic potential of anti-interleukin-17A aptamer: suppression of interleukin-17A signaling and attenuation of autoimmunity in two mouse models. Arthritis Rheum. 2011;63(2):455–66. DOI: http://dx.doi.org/10.1002%2Fart.30108.</p><p>Metawi S, Abbas D, Kamal M, Ibrahim M. Serum and synovial fluid levels of interleukin-17 in correlation with disease activity in patients with RA. Clin Rheumatol. 2011;30(9):1201–7. DOI: http://dx.doi.org/10.1007%2Fs10067-011-1737-y.</p><p>Moran E, Mullan R, McCormick J et al. Human rheumatoid arthritis tissue production of IL-17A drives matrix and cartilage degradation: synergy with tumour necrosis factor-α, Oncostatin M and response to biological therapies. Arthritis Res Ther. 2009;11(4):R113. DOI: http://dx.doi.org/10.1186%2Far2772.</p><p>Park J, Park M, Lee S, Oh H et al. TWEAK promotes the production of interleukin-17 in rheumatoid arthritis. Cytokine. 2012;60(1):143–9. DOI: http://dx.doi.org/10.1016%2Fj.cyto.2012.06.285.</p><p>Suurmond J, Dorjee A, Boon M, et al. Mast cells are the main interleukin 17-positive cells in anticitrullinated protein antibody-positive and -negative rheumatoid arthritis and osteoarthritis synovium. Arthritis Res Ther. 2011;13(5):R150. DOI: http://dx.doi.org/10.1186%2Far3466.</p><p>Ziolkowska M, Koc A, Luszczykiewicz G et al. High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporine A-sensitive mechanism. J Immunol. 2000;164:2832–8.</p><p>Suurmond J, Dorjee A, Boon M et al. Mast cells are the main interleukin 17-positive cells in anticitrullinated protein antibody-positive and -negative rheumatoid arthritis and osteoarthritis synovium. Arthritis Res Ther. 2011;13(5):R150. http://dx.doi.org/10.1186%2Far3466.</p><p>Chen D, Chen Y, Chen H et al. Increasing levels of circulating Th17 cells and interleukin-17 in rheumatoid arthritis patients with an inadequate response to anti-TNF-α therapy. Arthritis Res Ther. 2022;13(4):R126. DOI: http://dx.doi.org/10.1186%2Far3431.</p><p>Alzabin S, Abraham S, Taher T et al. Incomplete responses of inflammatory arthritis to TNFα blockade is associated with the Th17 pathway. Ann Rheum Dis. 2012;71:1741–8.</p><p>Adamopoulos I, Chao C, Geissler R et al. Interleukin-17A upregulates receptor activator of NF-κB on osteoclast precursors. Arthritis Res Ther. 2010;12(1): R29. DOI: http://dx.doi.org/10.1186%2Far2936.</p><p>Sato K, Suematsu A, Okamoto K et al. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med. 2006;203(12):2673–82. DOI: http://dx.doi.org/10.1084%2Fjem.20061775</p><p>Dharmapatni A, Smith M, Crotti T et al. TWEAK and Fn14 expression in the pathogenesis of joint inflammation and bone erosion in rheumatoid arthritis. Arthritis Res Ther. 2011;13(2):R51. DOI: http://dx.doi.org/10.1186%2Far3294.</p><p>Park J, Park M, Lee S et al. TWEAK promotes the production of interleukin-17 in rheumatoid arthritis. Cytokine. 2012;60(1):143–9. DOI: http://dx.doi.org/10.1016%2Fj.cyto.2012.06.285.</p><p>Hueber A, Asquith D, Miller A et al. Cutting edge: mast cells express IL-17A in rheumatoid arthritis synovium. J Immunol. 2010;184(7):3336–40. DOI: http://dx.doi.org/10.4049%2Fjimmunol.0903566.</p><p>Lin AM, Rubin CJ, Khandpup R et al. Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis. J Immunol. 2011;187(1);490–500. DOI: http://dx.doi.org/10.4049%2Fjimmunol.1100123.</p><p>Kenna TJ, Brown MA. The role of IL-17-secreting mast cells in inflammatory joint disease. Nat Rev Rheumatol. 2012;9(6):375-9. DOI: http://dx.doi.org/10.1038%2Fnrrheum.2012.205. Epub 2012 Dec 11..</p><p>Корсакова ЮЛ, Станислав МЛ, Денисов ЛН, Насонов ЕЛ. Устекинумаб – новый препарат для лечения псориаза и псориатического артрита. Научно-практическая ревматология. 2012;2(51):170–80. [Korsakova YL, Stanislav ML, Denisov LN, Nasonov EL. Ustekinumab is a new drug to treat psoriasis and psoriatic arthritis. Nauchno-prakticheskaya revmatologiya. 2012;51(2):170–80.]</p><p>Patel DD, Lee DM, Kolbinger F, Antoni C. Effect of IL-17A blockade with secukinumab in autoimmune diseases. Ann Rheum Dis. 2013;72 Suppl 2:ii116–23. DOI: 10.1136/annrheumdis-2012-202371. Epub 2012 Dec 19.</p><p>Hueber W, Patel D, Dryja T et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med. 2010; 2(52):52ra72. DOI: 10.1126/scitranslmed.3001107.</p><p>Genovese M, Durez P, Richards H et al. Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study. Ann Rheum Dis. 2012;72(6):863–9. DOI: 10.1136/annrheumdis-2012-201601. Epub 2012 Jun 23.</p><p>Gnanasakthy A, Kosinski M, Genovese M et al. Association between health-related quality of life (HRQOL) and ACR improvement among rheumatoid arthritis (RA) patients treated with secukinumab [abstract]. Ann Rheum Dis. 2012;71 Suppl 3:666.</p><p>Strand V, Genovese M, Mallya U et al. Improvements in health-related quality of life (HRQOL) in patients with rheumatoid arthritis (RA) receiving secukinumab: results of a dose-finding study [abstract]. Ann Rheum Dis. 2012;71 Suppl 3:671.</p><p>Genovese M, Kellner H, Durez P et al. Secukinumab treatment improves ACR50, HAQ-DI and EULAR remission rates in patients with rheumatoid arthritis [abstract]. Ann Rheum Dis. 2012;71 Suppl 3:191.</p><p>Leonardi C, Matheson R, Zacharie C et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med. 2012;366(13):1190–9. DOI: 10.1056/NEJMoa1109997..</p><p>Genovese M, Van den Bosch F, Roberson S et al. LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis. Arthritis Rheum. 2010;62(4):929–39. DOI: 10.1002/art.27334.</p><p>Genovese M, Greenwald M, Cho C et al. A phase 2 study of multiple subcutaneous doses of LY2439821, an anti-IL-17 monoclonal antibody, in patients with rheumatoid arthritis in two populations: naïve to biologic therapy or inadequate responders to tumor necrosis factor alpha inhibitors [abstract]. Arthritis Rheum. 2011;63 Suppl 10:S1017.</p><p>Papp K, Leonardi C, Menter A et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med. 2012;366(13):1181–9. DOI: 10.1056/NEJMoa1109017.</p><p>Pavelka K, Chon Y, Newmark R et al. A randomized, double-blind, placebo-controlled, multiple-dose study to evaluate the safety, tolerability, and efficacy of brodalumab (AMG 827) in subjects with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Rheum. 2010;64 Suppl 10:S362.</p><p>Leonardi C, Matheson R, Zacharie C et al. (2012) Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med. 2012;366(13):1190–9. DOI: 10.1056/NEJMoa1109997..</p><p>Papp K, Langley R, Sigurgeirsson B et al. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. Br J Dermatol. 2012;168(2):412–21. DOI: 10.1111/bjd.12110. Epub 2013 Jan 18.</p><p>Papp K, Leonardi C, Menter A et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med. 2012;366(13):1181–9. DOI: 10.1056/NEJMoa1109017.</p><p>McInnes I, Sieper J, Braun J et al. Anti-interleukin 17A monoclonal antibody secukinumab reduces signs and symptoms of psoriatic arthritis in a 24-week multicenter, double-blind, randomized, placebo-controlled trial (abstract). Arthritis Rheum. 2011;63 Suppl 10:779.</p><p>U.S. National Institutes of Health. ClinicalTrials.gov. Available from: http://www.clinicaltrials.gov (accessed 30 Sep 2012).</p><p>Baeten D, Sieper J, Emery P et al. The anti-IL17A monoclonal antibody secukinumab (AIN457) showed good safety and efficacy in the treatment of ankylosing spondylitis (abstract). Ann Rheum Dis. 2011;70 Suppl 3:127.</p><p>Baraliakos X, Braun J, Laurent DD et al. Interleukin-17A blockade with secukinumab reduces spinal inflammation in patients with ankylosing spondylitis as early as week 6, as detected by magnetic resonance imaging (abstract). Arthritis Rheum. 2011;63 Suppl 10:2486D.</p><p>Yen D, Cheung J, Scheerens H et al. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest. 2006;116(5):1310–6. DOI: http://dx.doi.org/10.1172%2FJCI21404</p><p>Hueber W, Sands BE, Lewitzky S et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012;61(12):1693¬700. DOI: 10.1136/gutjnl-2011-301668. Epub 2012 May 17.</p><p>Ogawa A, Andoh A, Araki Y et al. Neutralization of interleukin-17 aggravates dextran sulfate sodium-induced colitis in mice. Clin Immunol. 2004;110(1):55–62. DOI: http://dx.doi.org/10.1016%2Fj.clim.2003.09.013.</p></div><br />
Review
For citations:
Nasonov E.L., Denisov L.N., Stanislav M.L. INTERLEUKIN-17 IS A NEW TARGET FOR ANTI-CYTOKINE THERAPY OF IMMUNE INFLAMMATORY RHEUMATIC DISEASES. Rheumatology Science and Practice. 2013;51(5):545-552. (In Russ.) https://doi.org/10.14412/1995-4484-2013-1547
Views:
6411
Email this article 